Texas is currently home to 4851 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Recruiting
To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
04/16/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Recruiting
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/16/2025
Locations: Texas Oncology-Baylor Res Ins, Dallas, Texas
Conditions: Primary Immune Thrombocytopenia (ITP)
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recruiting
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: USOR Texas Oncology, Abilene, Texas
Conditions: Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Serous Ovarian Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Platinum-resistant Ovarian Cancer (PROC), Primary Refractory Ovarian Cancer, Uterine Cancer
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
04/16/2025
Locations: The University of Texas Health Science Center at Houston, Bellaire, Texas
Conditions: Atopic Dermatitis, Eczema
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
Recruiting
The purpose of this research study is to compare the technique of performing bilateral lung transplantation off-pump vs venoarterial ECMO (VA ECMO). The goal of the trial is to determine which technique has lower rates of primary graft dysfunction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Lung Transplant
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Recruiting
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Gender:
ALL
Ages:
59 months and below
Trial Updated:
04/16/2025
Locations: UT Southwestern/Simmons Cancer Center, Dallas, Texas
Conditions: Medulloblastoma
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/16/2025
Locations: Gadolin Research LLC, Beaumont, Texas
Conditions: Alzheimer Disease
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Recruiting
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma, Mantle Cell Lymphoma
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/16/2025
Locations: Houston Research Institute, Houston, Texas
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
04/16/2025
Locations: Dallas Renal Group - Arlington, Arlington, Texas
Conditions: Proteinuric Kidney Disease
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Texas
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Sibling-Mediated Intervention on Literacy and Reciprocity for Children With Autism
Recruiting
Given the increasing prevalence of autism spectrum disorder (ASD), estimated to be 1 in 68 in the United States alone, ASD has become one of the fastest-growing pediatric concerns. The deficits of children with ASD range across social communication and academic skills. One of the effective interventions that have been used commonly for ASD is the model-lead-test, which includes modeling, prompting children to practice target skills together, and providing children with affirmative feedback or er... Read More
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
04/16/2025
Locations: Children's Autism Center, Round Rock, Texas
Conditions: Autism Spectrum Disorder